41 related articles for article (PubMed ID: 10762559)
1. Spacer Domain in Hepatitis B Virus Polymerase: Plugging a Hole or Performing a Role?
Pley C; Lourenço J; McNaughton AL; Matthews PC
J Virol; 2022 May; 96(9):e0005122. PubMed ID: 35412348
[TBL] [Abstract][Full Text] [Related]
2. Fitness and infectivity of drug-resistant and cross-resistant hepatitis B virus mutants: why and how is it studied?
Durantel D
Antivir Ther; 2010; 15(3 Pt B):521-7. PubMed ID: 20516574
[TBL] [Abstract][Full Text] [Related]
3. Dynamics of hepatitis B virus resistance to lamivudine.
Pallier C; Castéra L; Soulier A; Hézode C; Nordmann P; Dhumeaux D; Pawlotsky JM
J Virol; 2006 Jan; 80(2):643-53. PubMed ID: 16378967
[TBL] [Abstract][Full Text] [Related]
4. Treatment of follicular non-Hodgkin's lymphoma.
Maloney DG
Curr Hematol Rep; 2005 Jan; 4(1):39-45. PubMed ID: 15610658
[TBL] [Abstract][Full Text] [Related]
5. PCR amplification of DNA containing non-standard base pairs by variants of reverse transcriptase from Human Immunodeficiency Virus-1.
Sismour AM; Lutz S; Park JH; Lutz MJ; Boyer PL; Hughes SH; Benner SA
Nucleic Acids Res; 2004; 32(2):728-35. PubMed ID: 14757837
[TBL] [Abstract][Full Text] [Related]
6. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.
Delaney WE; Yang H; Westland CE; Das K; Arnold E; Gibbs CS; Miller MD; Xiong S
J Virol; 2003 Nov; 77(21):11833-41. PubMed ID: 14557667
[TBL] [Abstract][Full Text] [Related]
7. Effects of pyrimidine and purine analog combinations in the duck hepatitis B virus infection model.
Seignères B; Martin P; Werle B; Schorr O; Jamard C; Rimsky L; Trépo C; Zoulim F
Antimicrob Agents Chemother; 2003 Jun; 47(6):1842-52. PubMed ID: 12760857
[TBL] [Abstract][Full Text] [Related]
8. Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro.
Delaney WE; Edwards R; Colledge D; Shaw T; Furman P; Painter G; Locarnini S
Antimicrob Agents Chemother; 2002 Sep; 46(9):3057-60. PubMed ID: 12183271
[TBL] [Abstract][Full Text] [Related]
9. A preliminary benefit-risk assessment of lamivudine for the treatment of chronic hepatitis B virus infection.
Zoulim F
Drug Saf; 2002; 25(7):497-510. PubMed ID: 12093308
[TBL] [Abstract][Full Text] [Related]
10. In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil.
Chin R; Shaw T; Torresi J; Sozzi V; Trautwein C; Bock T; Manns M; Isom H; Furman P; Locarnini S
Antimicrob Agents Chemother; 2001 Sep; 45(9):2495-501. PubMed ID: 11502520
[TBL] [Abstract][Full Text] [Related]
11. Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus.
Delaney WE; Edwards R; Colledge D; Shaw T; Torresi J; Miller TG; Isom HC; Bock CT; Manns MP; Trautwein C; Locarnini S
Antimicrob Agents Chemother; 2001 Jun; 45(6):1705-13. PubMed ID: 11353615
[TBL] [Abstract][Full Text] [Related]
12. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance.
Ono SK; Kato N; Shiratori Y; Kato J; Goto T; Schinazi RF; Carrilho FJ; Omata M
J Clin Invest; 2001 Feb; 107(4):449-55. PubMed ID: 11181644
[TBL] [Abstract][Full Text] [Related]
13. Absence of mutations in the YMDD motif/B region of the hepatitis B virus polymerase in famciclovir therapy failure.
Günther S; von Breunig F; Santantonio T; Jung MC; Gaeta GB; Fischer L; Sterneck M; Will H
J Hepatol; 1999 May; 30(5):749-54. PubMed ID: 10365797
[TBL] [Abstract][Full Text] [Related]
14. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B.
Nafa S; Ahmed S; Tavan D; Pichoud C; Berby F; Stuyver L; Johnson M; Merle P; Abidi H; Trépo C; Zoulim F
Hepatology; 2000 Nov; 32(5):1078-88. PubMed ID: 11050059
[TBL] [Abstract][Full Text] [Related]
15. Detection of hepatitis B virus variants resistant to lamivudine and famciclovir among randomly selected chronic carriers from Spain.
León P; Pozo F; Echevarría JM
Enferm Infecc Microbiol Clin; 2004 Mar; 22(3):133-7. PubMed ID: 14987532
[TBL] [Abstract][Full Text] [Related]
16. Clinical experience with famciclovir against hepatitis B virus.
Bartholomeusz A; Groenen LC; Locarnini SA
Intervirology; 1997; 40(5-6):337-42. PubMed ID: 9675638
[TBL] [Abstract][Full Text] [Related]
17. Detection of hepatitis B virus resistance to antivirals.
Zoulim F
J Clin Virol; 2001 Jun; 21(3):243-53. PubMed ID: 11397661
[TBL] [Abstract][Full Text] [Related]
18. Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B.
Seignères B; Pichoud C; Ahmed SS; Hantz O; Trépo C; Zoulim F
J Infect Dis; 2000 Apr; 181(4):1221-33. PubMed ID: 10762559
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
